Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2023-11-30 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙关于控股股东部分股份解除质押及再质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and re-pledged, along with the dates and parties involved. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or earnings release.
2023-11-30 Chinese
马应龙关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the receipt of a drug registration certificate from the national drug regulatory authority. It details the drug's specifications, approval, and impact on the company. The document is short (1077 characters) and serves as an official announcement rather than a detailed report or financial filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not related to annual reports, earnings, management changes, or other financial filings. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-31 Chinese
马应龙2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年第三季度报告" which translates to "2023 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes for the third quarter of 2023. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2023. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-27 Chinese
马应龙关于控股股东部分股份解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and re-pledged, along with percentages of total shareholding and company stock. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure about share pledge status, which fits the category of capital structure updates related to financing activities. Therefore, it is best classified as a Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2023-09-20 Chinese
马应龙关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2023 half-year performance explanation meeting (业绩说明会) by Mayinglong Pharmaceutical Group Co., Ltd. It specifies the date, time, location, and format of the meeting, as well as instructions for investor participation and question submission. The document references the company's 2023 half-year report already published on August 26, 2023, but does not contain any financial data or detailed analysis itself. It is a notice about an upcoming investor presentation event rather than the presentation or report itself. Therefore, this document fits the category of Investor Presentation announcement (IP). However, since it is only an announcement of the meeting and not the presentation materials themselves, it is best classified as an Investor Presentation (IP) type document, as it focuses on the event for investors to discuss financial results and business performance.
2023-09-14 Chinese
马应龙2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年半年度报告' which translates to '2023 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company information, financial indicators, and operational details for the period January 1, 2023 to June 30, 2023. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification, and it is not a full annual report (10-K). Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.